|
"Effects of rosiglitazone on the frequency
of diabetes in patients with impaired glucose tolerance or
impaired fasting glucose: a randomised controlled trial," by the DREAM
Trial Investigators (H.C. Gerstein, et al.), The Lancet,
368(9541): 1096-1105, 23 September 2006.
[Authors' affiliation (correspondence address): Population Health Research
Institute, Hamilton, Ontario, Canada]
Abstract: "Background
Rosiglitazone is a thiazolidinedione that reduces insulin resistance and
might preserve insulin
secretion. The aim of this study was to assess prospectively the drugs
ability to prevent type 2 diabetes in individuals at high risk of developing
the condition. Methods 5269 adults aged 30 years or more with
impaired fasting glucose or impaired glucose tolerance, or both, and no
previous cardiovascular disease were recruited from 191 sites in 21
countries and randomly assigned to receive rosiglitazone (8 mg daily;
n=2365) or placebo (2634) and followed for a median of 3 years. The primary
outcome was a composite of incident diabetes or death. Analyses were done by
intention to treat. This trial is registered at ClinicalTrials.gov, number
NCT00095654. Findings At the end of study, 59 individuals had dropped
out from the rosiglitazone group and 46 from the placebo group. 306 (11.6%)
individuals given rosiglitazone and 686 (26.0%) given placebo developed the
composite primary outcome (hazard ratio 0.40, 95% CI 0.35-0.46; p<0.0001);
1330 (50.5%) individuals in the rosiglitazone group and 798 (30.3%) in the
placebo group became normoglycaemic (1.71,1-57-1.87; p<0.0001).
Cardiovascular event rates were much the same in both groups, although 14
(0.5%) participants in therosiglitazone group and two (0.1%) in the placebo
group developed heart failure (p=0.01). Interpretation Rosiglitazone
at 8 mg daily for 3 years substantially reduces incident type 2 diabetes and
increases the likelihood of regression to normoglycaemia in adults with
impaired fasting glucose or impaired glucose tolerance, or both."
This 2006 report from The Lancet was
cited 52 times in current journal articles indexed by Thomson
Scientific
during September-October 2007. Only one other medicine paper published in
the last two years, aside from reviews,
attracted a higher number of citations during that two-month period. Prior
to the most recent bimonthly count, citations to the paper have accrued as
follows:
July-August 2007: 30 citations
May-June 2007: 29
March-April 2007: 13
January-February 2007: 14
November-December 2006: 15
September-October 2006: 4
Total citations to date: 157
SOURCE: Hot
Papers Database. Included with a subscription to the print newsletter Science
Watch®, available from the
Research Services Group. Packaged on a CD that is mailed with each Science
Watch issue, the Hot
Papers Database contains data on hundreds of highly cited papers published
during the last two years. User interface permits searching by author,
organization, journal, field, and more. Total citations, as well as citations
accrued during successive bimonthly periods, can be assessed and graphed. An
updated CD containing the most recent bimonthly data is mailed with every new
issue of Science
Watch,
six times a year. The CD also includes an electronic version of the Science
Watch
issue in HTML format, for personal desktop access 
Previous Page | Return to SCI-BYTES
Main Menu
| Return to 2007 Menu
If you came from the Thomson Scientific Web site, click
here to return
.
- View the past and present top ten scientists and/or top three
Hot Papers in Chemistry.
- Analysis
of Chemistry.
- Assorted features pertaining to Chemistry
from all of the Essential Science Indicators editorials.
Features include interviews, essays, comments, profiles, and
rankings of the top- performing scientists, institutions,
countries, journals, papers, and fields.
|
|
cites
:
